In March 2019, the FDA approved esketamine for the treatment of severe depression, which is marketed as Spravato by Janssen Pharmaceuticals. In 2019, Johnson & Johnson announced the release of photochromic contact lenses. The lenses adjust to sunlight and help eyes recover from bright light exposure faster. The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives.
In March 2019 the FDA approved esketamine for the treatment of severe depression which is marketed as Spravato by Janssen Pharmaceuticals In 2019 Johnson & Johnson announced the release of photochromic contact lenses The lenses adjust to sunlight and help eyes recover from bright light exposure faster The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives